Fludarabine

SKU: orb1309978

Description

Fludarabine is a fluorinated purine analog that inhibits nucleic acid synthesis and STAT1 activation. It is widely used in leukemia and lymphoma research, with applications in both in vitro cell culture studies and in vivo animal models to investigate its antitumor mechanisms.

Research Area

Cell Biology, Molecular Biology, Signal Transduction, Stem Cell & Developmental Biology

Images & Validation

−

Key Properties

−

CAS Number	21679-14-1
MW	285.23
Purity	99.65%
Formula	C₁₀H₁₂FN₅O₄
SMILES	NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3O)C2=NC(F)=N1
Target	DNA/RNA Synthesis,Nucleoside Antimetabolite/Analog,Apoptosis,STAT
Solubility	10% DMSO+40% PEG300+5% Tween 80+45% Saline:2.86 mg/mL (10.03 mM);DMSO:240 mg/mL (841.43 mM)

Bioactivity

−

Target IC50	PBMC cells:1.9 μM\|T47D cells:46.2 μM\|MM.1S cells:13.48 µg/mL\|MCF-7 cells:15 μM\|Mahlavu cells:10 μM\|MM.1R cells:33.79 µg/mL\|HepG2 cells:20 μM\|RPMI8226 cells:1.54 µg mL A549 cells:47.44 μM\|HeLa cells:16 μM\|K562 cells:0.26 μM\|CCRF-CEM cells:19.49 μM\|HCT116 cells:6.6 μM Read more...
In Vivo	METHODS: To assay antitumor activity in vivo Fludarabine (8-40 mg/kg) was injected intraperitoneally into SCID mice bearing multiple myeloma RPMI8226 once daily for three days. Results the antitumor activity of Fludarabine in vivo was demonstrated by a less than 5-fold increase in tumors treated with 40 mg/kg of Fludarabine over 25 days compared to an approximately 10-fold increase in control tumors. METHODS: To stud the effect on graft-versus-host disease (GVHD), Fludarabine (0.8 mg/kg) was administered intraperitoneally to (BALB/c x C57BL/6) F1 mice harboring B-cell leukemia (BCL-1) every two weeks for five days in two cycles, followed by intraperitoneal injection of cyclophosphamide (400 mg/kg). Results: Mice treated with a Fludarabine-containing regimen prior to transplantation also had much less GVHD clinically and at necropsy, while graft-versus-leukemia appeared to be increased in the same animals. Read more...
In Vitro	METHODS: Multiple myeloma cells RPMI8226, MM.1S and MM.1R were treated with Fludarabine (0-64 µg/mL) for 24-48 h. Cell viability was measured by MTT Assay. Results: Fludarabine dose-time-dependently inhibite the proliferation of RPMI8226 cells with an IC50 of 1.54 µg mL at 24 h. At 48 h the IC50 of Fludarabine on MM.1S and MM.1R cells was 13.48 µg mL and 33.79 µg/mL, respectively METHODS: Rat aortic VSMCs were treated with Fludarabine (50 µM) and FBS for 30 min, an the expression levels of target proteins were detected by Western Blot. Results: FBS stimulation produced progressive JAK2 and STAT-1 activation, and Fludarabine induced a significant reduction in STAT-1 phosphorylation, while it did not alter JAK2 activation. Read more...
Cell Research	VSMCs were isolated fro the aorta of Male Wistar rats weighing ～350–500 g, as previously described. For cell culture experiments, 2 × 10^5 rat VSMCs were plated in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). Semiconfluent VSMCs were starved by incubation in 0.5% FBS/DMEM for 36–48 h and then serum-stimulated with normal growth medium (i.e., DMEM containing 10% FBS) in the presence or absence of fludarabine 50 μM). Read more...
Animal Research	The animals in this study were andled according to the animal welfare regulation o the Magna Graecia University of Catanzaro, an the protocol was approved b the animal use committee of this institution. Fifty Wistar rats weighing 340 ± 40 g were anesthetized with an intramuscular injection of 100 mg/kg ketamine and 5 mg/kg xylazine. Angioplasty o the common carotid artery was performed using a balloon embolectomy catheter, as previously described and well validated in our laboratory. Fludarabine was dissolved in 30% pluronic F127 gel to the final concentration of 2.5, 5, 15, or 25 mg/mL. A the time of balloon injury, gel containing fludarabine or Vehicle was applied aroun the middle segment (2 cm in length) o the right injured carotid artery ( 0.1 mL per 1-cm length o the artery segment, equivalent to 0.5, 1, 3, or 5 mg of total fludarabine locally delivered), as previously described. As a control experiment, 200 μL of fludarabine/gel solution (25 mg/mL) were applied aroun the sham-operated carotid artery. To stud the fludarabine toxicity, laboratory studies were performed at baseline and 2 wk after drug local delivery (25 mg/mL). Arterial pressure and heart rate were measured indirectly by a tail-cuff plethysmographic technique. Read more...

Storage & Handling

−

Storage	store at low temperature,keep away from direct sunlight,keep away from moisture \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice/Shipping at ambient temperature.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

DNASynthesis, DNA synthesis, DNA Synthesis, DNA/RNA Synthesis, Apoptosis, Analog, NSC 118218, inhibit, NucleosideAntimetabolite, Nucleoside Antimetabolite/Analog, Nucleoside Antimetabolite, lymphoproliferative malignancies, NSC118218, NSC-118218, Fludarabine, Fludarabinum, fluorinated, F-ara-A, Inhibitor, purine analogue, RNASynthesis, RNA Synthesis, STAT, STAT1

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID

657237 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

Fludarabine (orb1309978)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

MW:	591.12
Formula:	C₁₀H₁₂FN₅Na₃O₁₃P₃

CAS Number:	2734853-80-4
MW:	303.68
Formula:	C₁₀H₁₁ClFN₅O₃

CAS Number:	74832-57-8
MW:	525.17
Formula:	C₁₀H₁₅FN₅O₁₃P₃

Purity:	99.78%
CAS Number:	75607-67-9
MW:	365.21
Formula:	C₁₀H₁₃FN₅O₇P

Purity:	>98%(HPLC)
CAS Number:	21679-14-1
MW:	285.2
Formula:	C₁₀H₁₂FN₅O₄

Fludarabine

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

Fludarabine triphosphate trisodium [orb1983218]

Fludarabine-Cl [orb1689326]

Fludarabine triphosphate [orb1690290]

Fludarabine Phosphate [orb1300713]

Fludarabine [orb1225653]

Quality Guarantee

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

Fludarabine (orb1309978)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors